In a group B, Rh-negative patient with a positive DAT, which situation would occur?

In a group B, Rh-negative patient with a positive DAT, which situation would occur?

• A. all major crossmatches would be incompatible
• B. the weak D test and control would be positive
• C. the antibody screening test would be positive
• D. the forward and reverse ABO groupings would not agree

Answer: (B)

In a situation where a group B, Rh-negative patient has a positive direct antiglobulin test (DAT), it indicates the presence of antibodies bound to the patient's red blood cells. One critical aspect to assess in this scenario involves the weak D test, which is conducted to determine if the patient has a weak expression of the D antigen, despite being classified as Rh-negative. When the DAT is positive, it suggests that antibodies are present, potentially indicating an underlying condition such as hemolytic anemia or a transfusion reaction. In the context of a weak D test, if the control also shows positive results, it implies that there are potentially weak D antigens present on the patient's cells. This might confuse the classification of Rh status, potentially leading to misinterpretation of whether the patient should be considered Rh-negative or not. Thus, the situation that would occur involves both the weak D test and the control returning positive results, reflecting the complexity surrounding Rh typing in patients with a positive DAT. This reinforces the need for careful testing to establish the correct clinical management for Rh-negative patients.

In a situation where a group B, Rh-negative patient has a positive direct antiglobulin test (DAT), it indicates the presence of antibodies bound to the patient's red blood cells. One critical aspect to assess in this scenario involves the weak D test, which is conducted to determine if the patient has a weak expression of the D antigen, despite being classified as Rh-negative.

When the DAT is positive, it suggests that antibodies are present, potentially indicating an underlying condition such as hemolytic anemia or a transfusion reaction. In the context of a weak D test, if the control also shows positive results, it implies that there are potentially weak D antigens present on the patient's cells. This might confuse the classification of Rh status, potentially leading to misinterpretation of whether the patient should be considered Rh-negative or not.

Thus, the situation that would occur involves both the weak D test and the control returning positive results, reflecting the complexity surrounding Rh typing in patients with a positive DAT. This reinforces the need for careful testing to establish the correct clinical management for Rh-negative patients.